PRRT2 and cancer: The clinical efficacy of a PKC-activating drug in treating a range of cancers provided a unique opportunity to gain further insights both into the complex role of PKC in cancer and into fundamental structure–activity relationships of epoxytiglianes relevant to their future development as new drug candidates.